Monoclonal antibody for the detection of Clostridium botulinum type A toxin

Ferreira, Jospeh L.; Hamdy, M. K.; Herd, Zana L.; McCay, Steven G.; Zapatka, Francis A.

doi:10.1016/0890-8508(87)90015-6

Cited by 14 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One area in which differences between botulinum toxin serotypes are expected and desirable is that of immunological reactivity. It has been long assumed that antibodies generated against one botulinum toxin serotype would not cross-react with other serotypes (Burke, 1919;Shone et al, 1985;Ferreira et al, 1987). However, several recent reports suggest that the notion of strict immunological separation of the botulinum toxin types may need qualification.…”

Section: Discussionmentioning

confidence: 99%

Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparations

Aoki

1999

Euro J of Neurology

View full text Add to dashboard Cite

Tel: + 1 714 246 54 13; fax: + 1 714 246 4374Ongoing investigations evaluated clinically relevant properties of BOTOX" (botulinum toxin type A) relative to other botulinum neurotoxin preparations based on the same (type A) or different (types B, C,, E and F) serotypes. The mouse Digit Abduction Scoring (DAS) assay was used to compare muscle weakening efficacy, the antigenic potential of two BOTOX" preparations was measured in rabbits, and the presence of antibodies to serotypes A and B was analysed in humans. BOTOX" and new BOTOX" produced similar degrees of dose-related muscle weakness in mice. Both preparations of BOTOX" were approximately four times more potent than Dysport". Preparations of serotypes B, C, and F also demonstrated lower potency than BOTOX", with serotype F also having a shorter duration of action. Neutralising antibodies were found in rabbits 3 months post-treatment with BOTOX", but were undetected 8 months post-treatment with new BOTOX". A high incidence of antibodies to type B was observed in individuals with no known exposure to type B toxin: highest in groups with the highest incidence of type A antibodies. The safety margin for BOTOX", calculated using DAS median effective dose (ED,) and the minimum dose producing a 10% reduction in body weight, was more than twice that of Dysport". In conclusion, each botulinum toxin serotype tested exhibited a different muscle weakening efficacy; BOTOX" consistently exhibited the greatest eficacy. Importantly, BOTOX" and Dysport exhibited markedly different efficacy and safety profiles, and should not be considered interchangeable. Antibody distribution in humans suggests that there may be immunological cross-reactivity between serotypes A and B. Eur J Neurol 6 (suppl4):S3-S10 0 Blackwell Science Ltd

show abstract

Section: Discussionmentioning

confidence: 99%

Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparations

Aoki

1999

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…Monoclonal antibodies may also be used in the ELISA assay for botulinal toxin; these however are not generally available and require special expertise in their preparation. Monoclonal antibodies have been prepared against type A toxin by Ferreira et al (1987) and Shone et al (1985); these did not cross react with other C. botulinurn types. evaluated a type A monoclonal antibody in a meat system and found that 14/15 strains positive by the mouse neurotoxin test were also positive by the ELISA test.…”

Section: Comparison Of Elisa and Mouse Tests Formentioning

confidence: 99%

QUALITATIVE CORRELATION OF THE MOUSE NEUROTOXIN AND ENZYME‐LINKED IMMUNOASSAY FOR DETERMINING CLOSTRIDIUM BOTULINUM TYPES A AND B TOXINS¹

Huhtanen

Whiting

Miller

et al. 1991

Journal of Food Safety

View full text Add to dashboard Cite

The efficacy of an enzyme‐linked immunosorbent assay for botulinal toxin using polyclonal antibodies was evaluated in relation to the standard mouse assay. Qualitative tests for toxin in a meat system inoculated with Clostridium botulinum and pure cultures of various aerobic and anaerobic bacteria showed that both the mouse neurotoxin and enzyme‐linked immunosorbent assays detected toxin in the samples. However the ratios of mouse:ELISA activity of culture supernatant toxins of C. botulinum showed wide disparity among strains of types A and B. Trypsin treatment resulted in a slight loss of ELISA activity but the mouse response increased.

show abstract

“…Betley et al (1989) recently cloned a portion of the botulinum type A light chain DNA sequence. Although many immunological assay systems have been reported for botulinal toxin detection (Ferreira et al 1983;Ferreira et al 1987;Sakaguchi 1979), the mouse bioassay remains the most sensitive test available (AOAC 1990;Food and Drug Admin. 1984).…”

Section: Introductionmentioning

confidence: 99%

AN IMPROVED ASSAY FOR IDENTIFICATION of TYPE A CLOSTRIDIUM BOTULINUM USING the POLYMERASE CHAIN REACTION¹

Ferreira

Hamdy

McCay

et al. 1992

Rapid Methods Automation Mic

Self Cite

View full text Add to dashboard Cite

The polymerase chain reaction (PCR) was used to amplify a 1340‐bp fragment from the toxigenic Clostridium botulinum type A chromosome. Two oligonucleotide primers were synthesized to bracket the sequence coding for most of the type A toxin light chain (1340‐bp in size). the PCR amplified a 1340‐bp fragment from the DNA of all eleven C. botulinum type A strains tested. In contrast, no DNA fragments were amplified from C. botulinum types B, E, and F or from the other Clostridial chromosomal DNA examined. the products amplifed from botulinal type A strains were digested to produce fragments of the size predicted from the known location of the Hind dIII sites within the toxin gene sequence. When used as a DNA probe, the 1340‐bp PCR generated fragment from type A C. botulinum strain 73A hybridized to the PCR products from all 11 type A botulinal strains and to type A thromosomal DNA preparations.

show abstract

Monoclonal antibody for the detection of Clostridium botulinum type A toxin

Cited by 14 publications

References 10 publications

Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparations

Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparations

QUALITATIVE CORRELATION OF THE MOUSE NEUROTOXIN AND ENZYME‐LINKED IMMUNOASSAY FOR DETERMINING CLOSTRIDIUM BOTULINUM TYPES A AND B TOXINS¹

AN IMPROVED ASSAY FOR IDENTIFICATION of TYPE A CLOSTRIDIUM BOTULINUM USING the POLYMERASE CHAIN REACTION¹

Contact Info

Product

Resources

About

Monoclonal antibody for the detection of Clostridium botulinum type A toxin

Cited by 14 publications

References 10 publications

Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparations

Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparations

QUALITATIVE CORRELATION OF THE MOUSE NEUROTOXIN AND ENZYME‐LINKED IMMUNOASSAY FOR DETERMINING CLOSTRIDIUM BOTULINUM TYPES A AND B TOXINS1

AN IMPROVED ASSAY FOR IDENTIFICATION of TYPE A CLOSTRIDIUM BOTULINUM USING the POLYMERASE CHAIN REACTION1

Contact Info

Product

Resources

About

QUALITATIVE CORRELATION OF THE MOUSE NEUROTOXIN AND ENZYME‐LINKED IMMUNOASSAY FOR DETERMINING CLOSTRIDIUM BOTULINUM TYPES A AND B TOXINS¹

AN IMPROVED ASSAY FOR IDENTIFICATION of TYPE A CLOSTRIDIUM BOTULINUM USING the POLYMERASE CHAIN REACTION¹